Centre for Drug Research and Development (CDRD) and AstraZeneca have entered a strategic collaboration agreement to develop improved therapies for patients.
According to the agreement, AstraZeneca will provide 250,000 compounds from its chemical compound library to CDRD to identify novel drug targets and develop promising drug therapies for a range of diseases.
The agreement enables CDRD to develop validation and screening for novel drug targets.
Taizhou Institute of Health Sciences of Fudan University has entered a co-development agreement with Singlera Genomics to further advance the development of new approaches for disease prevention and treatments.
Pursuant to the agreement, the two partners will use Singlera Genomics’ proprietary technology, sequencing and Taizhou Cohorts’ unique sample collection and phenotypic information to identify specific biomarkers for early cancer detection.
Teva Pharmaceutical Industries Ltd plans to raise gross proceeds of $2bn through the public offering of 4.1% senior notes, due 1 October 2046.
The company intends to invest the funds for the acquisition of Actavis Generics and related fees and expenses.
Retinal therapeutics development company Precision Ocular has raised $20.53m in a series A venture financing round led by Imperial innovations Group plc, Consort Medical plc, NeoMed Management AS, V-bio Ventures and Hovione Scientia Ltd.
The company intends to use the proceeds to develop programmes to treat retinal diseases and next-generation drug delivery systems to administer cell and gene therapies to the back-of-eye.
Teva Pharmaceutical Industries Ltd has priced the public offering of 2.2% senior notes, due 21 July 2021. The company expects to raise gross proceeds of $3bn through the offering.
The company intends to use the funds to acquire Actavis Generics and for other general corporate purposes.
Image: Centre for Drug Research and Development (CDRD) and AstraZeneca have entered a strategic collaboration agreement. Photo: Courtesy of Erik031.